Author: Ravi Shankar

Media Release

COPENHAGEN, Denmark; October 26, 2026

• Median overall survival (OS) outcomes and encouraging anti-tumor activity observed with petosemtamab plus pembrolizumab in first-line (1L) recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (r/m HNSCC), with responses observed across HPV-positive and HPV-negative disease
• Phase 3 program in 1L HNSCC is ongoing, with topline data anticipated later this year

Genmab A/S (Nasdaq: GMAB) today announced updated results from a Phase 2 trial evaluating petosemtamab, an investigational IgG1-bispecific antibody targeting the epidermal growth factor receptor (EGFR) and leucine-rich repeat containing G-protein-coupled receptor 5 (LGR5), in combination with pembrolizumab for first-line (1L) treatment of recurrent/metastatic PD-L1+ head and neck squamous cell carcinoma (r/m HNSCC). In the 1L combination arm, treatment with petosemtamab plus pembrolizumab achieved a median overall survival (OS) of 28.2 months, associated with an overall response rate (ORR) of 63% and median progression free survival (mPFS) of 9.0 months in efficacy-evaluable patients (n=43), including a complete response (CR) rate of 19%. The findings were presented at the European Society for Medical Oncology (ESMO) Congress 2026, held in Madrid, Spain.

“For patients with recurrent or metastatic head and neck squamous cell carcinoma, there is an ongoing need for new treatment approaches that may help expand options beyond currently available regimens,” said Amaury Daste, M.D., Medical Oncologist, Hospital Center University de Bordeaux, France, and study investigator. “The median overall survival of 28 months observed with petosemtamab plus pembrolizumab in this trial, along with a manageable safety profile, are impressive. It is also particularly noteworthy that responses were observed across patient subgroups and continued to be maintained at the time of analysis, an important consideration for patients facing a disease where durable disease control remains a critical treatment goal.”

As of May 15, 2026, median duration of follow-up was 25.5 months; clinical activity was observed across combined positive PD L-1 expression levels and p16 subgroups. With more mature follow-up, the median OS was reached (12-month OS rate, 79%), with an ORR of 63%. Median duration of response (mDOR) was not reached, with an estimated 55% of responders maintaining a response at 24 months. Median PFS was 9.0 months (95% CI, 5.2–12.9; 12-month PFS rate, 40%).

The most common treatment-emergent adverse events (TEAEs) (all grade/Grade 3-4) were asthenia (51%/7%), acneiform dermatitis (51%/7%), and rash (49%/2%). Infusion-related reactions occurred in 38% of patients (7% Grade 3-4), and all resolved. No Grade 5 events nor treatment-related deaths were reported.

“These findings strengthen our confidence in petosemtamab’s potential to make a meaningful difference in first-line head and neck cancer,” said Tahamtan Ahmadi, M.D., Ph.D., Executive Vice President and Chief Medical Officer, Head of Experimental Medicines, Genmab. “Seeing responses across both HPV-positive and HPV-negative disease reinforces our ambition to reach a broad patient population and our commitment to advancing the petosemtamab clinical development program.”

Petosemtamab has the only triple mechanism of action that uniquely targets the LGR5+ stem-like cancer cells that drive tumor recurrence and metastases in epithelial cancers. In addition to this ongoing Phase 1/2 trial (NCT03526835), the petosemtamab clinical program includes four Phase 3 LiGeR trials: in 1L PD-L1+ recurrent or metastatic head and neck squamous cell carcinoma (r/m HNSCC) (LiGeR-HN1; NCT06525220); in 2L/3L r/m HNSCC (LiGeR-HN2; NCT06496178), in 1L RAS/BRAF wild-type, left-sided unresectable or metastatic CRC (LiGeR-CRC1; NCT07702032); and in 2L RAS/BRAF wild-type recurrent, unresectable, or metastatic CRC (LiGeR-CRC2; NCT07775287).

On Wednesday, October 28 at 5:00 p.m. CET/12:00 p.m. EDT, Genmab will host an investor update. To register, visit genmab.com/events-presentations.

About the Phase 2 Petosemtamab Trial (NCT03526835)
The Phase 2 trial (NCT03526835) is an ongoing, open-label, multicenter study evaluating petosemtamab as monotherapy and in combination with pembrolizumab across multiple solid tumors, including head and neck squamous cell carcinoma. In the first-line combination arm, 45 patients were treated with 1500 mg of petosemtamab every two weeks plus 400 mg of pembrolizumab every six weeks until disease progression or unacceptable toxicity. The trial includes a first-line combination cohort evaluating petosemtamab plus pembrolizumab, as well as monotherapy cohorts across later lines of therapy. Primary endpoints include objective response rate (ORR) and safety.

About Head and Neck Squamous Cell Carcinoma (HNSCC)
Head and Neck Squamous Cell Carcinoma (HNSCC) is a group of biologically similar cancers that arise from the tissue lining the surfaces of the oral cavity, pharynx and larynx and represent more than 90% of all head and neck cancers.ⁱ It is the seventh most common cancer globally.ⁱⁱ Risk for HNSCC is approximately two to four times higher in men than women.ⁱⁱⁱ Treatment options vary depending on individual factors, including the location of the tumor, stage of the tumor, and a person’s overall health.ⁱⁱⁱ Despite current treatment options, there remains a high patient need for additional therapies, as approximately 50% of patients with locally advanced HNSCC will experience disease recurrence following initial treatment. Recurrent or metastatic HNSCC is associated with a median overall survival of approximately 10-12 months.^iv

About Petosemtamab (GEN1158)
Petosemtamab is an investigational human IgG1-based bispecific antibody targeting the EGFR and the LGR5 and designed to support multiple anti-tumor mechanisms. It inhibits EGFR-mediated signaling by engaging a unique site on the receptor to prevent ligand binding. In addition, petosemtamab triggers EGFR degradation in cancer stem-like cells expressing both EGFR and LGR5. Petosemtamab is also engineered to enhance innate immune-mediated activity through interactions with macrophages and natural killer cells. It is currently being investigated in head and neck squamous cell carcinoma (HNSCC) and other solid tumors, including colorectal cancer (CRC). Please visit https://clinicaltrials.gov/ for more information.

About Genmab
Genmab is an international biotechnology company dedicated to improving the lives of people with cancer and other serious diseases through innovative antibody medicines. For over 25 years, its passionate, innovative and collaborative team has advanced a broad range of antibody-based therapeutic formats, including bispecific antibodies, antibody drug conjugate (ADCs), immune-modulating antibodies and other next-generation modalities. Genmab’s science powers eight approved antibody medicines, and the company is advancing a strong late-stage clinical pipeline, including wholly owned programs, with the goal of delivering transformative medicines to patients.

Established in 1999, Genmab is headquartered in Copenhagen, Denmark, with international presence across North America, Europe and Asia Pacific. For more information, please visit Genmab.com or follow us on LinkedIn, X, Facebook and Instagram.

Contact:
David Freundel, Senior Director, Global Communications & Corporate Affairs
T: +1 609 613 0504; E: dafr@genmab.com

Andrew Carlsen, Vice President, Head of Investor Relations
T: +45 3377 9558; E: acn@genmab.com

This Media Release contains forward-looking statements. The words “believe,” “expect,” “anticipate,” “intend” and “plan” and similar expressions identify forward-looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with preclinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.com and the risk factors included in Genmab’s most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. Genmab does not undertake any obligation to update or revise forward looking statements in this Media Release nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.

Genmab A/S and/or its subsidiaries own the following trademarks: Genmab^®; the Y-shaped Genmab logo^®; Genmab in combination with the Y-shaped Genmab logo^®; HuMax^®; DuoBody^®; HexaBody^®; DuoHexaBody^®, HexElect^®, and KYSO^®.

---

ⁱ Johnson DE, Burtness B, Leemans CR, Lui VWY, Bauman JE, Grandis JR. “Head and neck squamous cell carcinoma.” Nat Rev Dis Primers, 2020 Nov 26;6(1):92. doi: 10.1038/s41572-020-00224-3. Erratum in: Nat Rev Dis Primers. 2023 Jan 19;9(1):4. doi: 10.1038/s41572-023-00418-5. PMID: 33243986; PMCID: PMC7944998.
ⁱⁱ Barsouk A, Aluru JS, Rawla P, Saginala K, Barsouk A. “Epidemiology, Risk Factors, and Prevention of Head and Neck Squamous Cell Carcinoma.” Med Sci (Basel), 2023 Jun 13;11(2):42. doi: 10.3390/medsci11020042. PMID: 37367741; PMCID: PMC10304137.
ⁱⁱⁱ Cancer Research Institute. “Head and Neck Cancer a Promising Treatment?” Accessed June 4, 2026. https://www.cancerresearch.org/immunotherapy-by-cancer-type/head-and-neck-cancer.
^iv Ionna F, Bossi P, Guida A, Alberti A, Muto P, Salzano G, Ottaiano A, Maglitto F, Leopardo D, De Felice M, Longo F, Tafuto S, Della Vittoria Scarpati G, Perri F. “Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: A Big and Intriguing Challenge Which May Be Resolved by Integrated Treatments Combining Locoregional and Systemic Therapies.” Cancers (Basel), 2021 May 14;13(10):2371. doi: 10.3390/cancers13102371. PMID: 34069092; PMCID: PMC8155962.

Media Release no. 15
CVR no. 2102 3884
LEI Code 529900MTJPDPE4MHJ122

Genmab A/S
Carl Jacobsens Vej 30
2500 Valby
Denmark

Attachment

• 261026_MR15_Peto_HNSCC_ESMO2026

Octopus AIM VCT plc

Re-opening of Offer for Subscriptions to Further Applications

Octopus AIM VCT plc (the ‘Company’) announces that, further to the Company’s joint offer with Octopus AIM VCT 2 plc for subscription to raise up to £30 million, with an over-allotment facility of up to £30 million, in the 2025/2026 and 2026/2027 tax years (the ‘Offer’), as set out in a Prospectus dated 12 January 2026, the Offer is now open to new subscriptions in respect of the Company only. The Offer will not re-open to new subscriptions in respect of Octopus AIM VCT 2 plc.

Applicants whose valid applications are received prior to 5pm on 16 December 2026 will benefit from the costs of the Offer being reduced by 2.5%. Applicants will receive these reductions in the form of additional new shares, which will be paid for by Octopus Investments Limited, the Company’s investment manager (the ‘Investment Manager’).

In addition, applicants who are existing shareholders of any Octopus managed VCT will be entitled to a 1% loyalty discount, this discount is available for the remainder of the Offer. Applicants will receive this reduction in the form of additional new shares, which will be paid for by the Investment Manager.

The proceeds of the Offer will be used to support the Company’s continued investment programme and pipeline of opportunities.

For further information please contact:

Ronan Goggin
Octopus Company Secretarial Services Limited
Tel: +44 (0)80 0316 2067

LEI: 213800C5JHJUQLAFP619

Heineken N.V. reports the progress of transactions under its current
share buyback programme

Amsterdam, 26 October 2026 – Heineken N.V. (EURONEXT: HEIA; OTCQX: HEINY) hereby reports transaction details related to the second € 750 million tranche of its € 1.5 billion share buyback programme as communicated on 12 February 2026.

From 19 October 2026 up to and including 23 October 2026 a total of 162,000 shares were repurchased on exchange at an average price of € 76.88. During the same period, 162,930 shares were repurchased from Heineken Holding N.V.

Up to and including 23 October 2026, a total of 9,190,451 shares were repurchased under the second tranche of the share buyback programme for a total consideration of € 654,318,899 (including shares repurchased from Heineken Holding N.V.).

Heineken N.V. publishes on a weekly basis, every Monday, an overview of the progress of the share buyback programme on its website: https://www.theheinekencompany.com/investors/share-information/share-buyback-programme

Enquiries
Media	Investors
Christiaan Prins	Tristan van Strien
Director of Global Communication	Global Director of Investor Relations
Marlie Paauw	Lennart Scholtus / Isabelle van Rongen
Global Media Lead	Investor Relations Manager / Investor Relations Manager
E-mail: pressoffice@heineken.com	E-mail: investors@heineken.com
Tel: +31-20-5239355	Tel: +31-20-5239590

Regulatory information
This press release is issued in connection with the disclosure and reporting obligations as set out in Article 5(1)(b) Regulation (EU) 596/2014 and Article 2(2) of the Commission Delegated Regulation (EU) 2016/1052 that contains technical standards for buyback programs.

Editorial information:
HEINEKEN is the world’s pioneering beer company. It is the leading developer and marketer of premium and non-alcoholic beer and cider brands. Led by the Heineken® brand, the Group has a portfolio of more than 340 international, regional, local and specialty beers and ciders. With HEINEKEN’s over 85,000 employees, we brew the joy of true togetherness to inspire a better world. Our dream is to shape the future of beer and beyond to win the hearts of consumers. We are committed to innovation, long-term brand investment, disciplined sales execution and focused cost management. Through “Brew a Better World”, sustainability is embedded in the business. HEINEKEN has a well-balanced geographic footprint with leadership positions in both developed and developing markets. We operate breweries, malteries, cider plants and other production facilities in more than 70 countries. Most recent information is available on our Company’s website and follow us on LinkedIn and Instagram.

Attachment

• PR_SBB 2025_Weekly update_26-Oct-2026

TORONTO, Oct. 26, 2026 (GLOBE NEWSWIRE) — Fury Gold Mines Limited (TSX and NYSE American: FURY) (“Fury” or the “Company”) is pleased to announce additional assay results from its ongoing Phase 2 drill program at the Eau Claire Gold Project, located in the Eeyou Istchee Territory in the James Bay region of northern Quebec.

The Phase 2 program comprises approximately 25,000 metres (m) of diamond drilling designed to increase geological confidence within the current mineral resource estimate and support the conversion of Inferred Mineral Resources to higher-confidence resource categories. All drill holes reported in this release were completed within areas currently classified as Inferred and continue to demonstrate strong grade and geological continuity throughout the deposit.

Significant drill highlights, shown in true widths, include:

• Hole 26EC-131 intersected 14.95 grams per tonne (“g/t”) gold (“Au”) over 4.25m;
• Hole 26EC-130 intersected 13.15 g/t Au over 1.50m;
• Hole 26EC-132 intersected 6.81 g/t Au over 1.39m; and
• Hole 26EC-122 intersected 7.03 g/t Au over 1.50m.
• 21,857m (or 46 drill holes) for the Phase 2 Eau Claire program has been completed.

Results are highlighted by drill hole 26EC-131, which intersected 14.95 g/t gold over 4.25 metres true width, approximately 60 metres up-dip from historical hole ER15-572, which previously returned 6.18 g/t gold over 5.05 metres (Figure 2). This intercept confirms the continuity of the high-grade mineralized system and further validates the Company’s geological model. The result significantly increases confidence in the continuity of the modeled mineralized zone and is expected to contribute to the conversion of portions of the current Inferred Resource to the Indicated category in a future mineral resource update.

Additional significant intercepts include 13.15 g/t gold over 1.50 metres in hole 26EC-130, 6.81 g/t gold over 1.39 metres in hole 26EC-132, and 7.03 g/t gold over 1.50 metres in hole 26EC-122 (Figure 1).

All drill holes disclosed to date from the Phase 2 program, including those reported in this news release and in the Company’s previous news releases, will be incorporated into the upcoming update of the mineral resource estimate for the Eau Claire Gold Project.

“The primary objective of this drilling campaign is to increase confidence and ounces into the resource model,” commented Tim Clark, CEO of Fury. “Hole 26EC-131 confirms the continuity of high-grade mineralization approximately 60 metres up-dip from historical hole ER15-572 and further validates the geological interpretation of the deposit. These results, in combination with our overall drilling program, continue to support the conversion of portions of the current Inferred Resources to the Indicated category in the next mineral resource update, which will be associated with the pre-feasibility in 2027.”

Table 1: Recent Drill Highlights

Hole ID	From	To	Drilled Thickness (m)	True Thickness (m)	Au (g/t)
26EC-122	206.0	207.5	1.5	1.50	7.03
26EC-130	539.0	540.5	1.5	1.50	1.57
	551.0	552.5	1.5	1.50	1.56
	573.5	575.0	1.5	1.50	13.15
26EC-131	189.0	190.5	1.5	1.37	1.50
	380.0	381.5	1.5	1.41	1.81
	390.5	393.0	2.5	2.35	1.72
	404.5	406.0	1.5	1.41	1.74
	412.0	416.5	4.5	4.25	14.95
26EC-132	290.5	292.0	1.5	1.39	6.81
	304.0	305.5	1.5	1.40	6.56

Intercepts were calculated using Au grade*thickness no less than 2 g/t*m width grade no less than 1g/t, maximum consecutive dilution 2m. True thickness was used for intercept calculation.

Phase 2 drilling is aimed at converting inferred mineral resources into higher-confidence mineral resource categories and expanding the indicated mineral resource. To date, 46 drill holes totalling approximately 21,857 metres have been completed, of which five holes were abandoned, and three holes are in progress. Assay results are currently available for 26 holes totalling 13,374 metres.

Figure 1: Long section of the Eau Claire Deposit looking north showing the locations of the completed and current drill holes in relation to the block model.

Figure 2: Eau Claire – Section 26EC-131

Valérie Doyon, P.Geo, VP, Geology at Fury, is a “qualified person” within the meaning of Canadian mineral projects disclosure standards instrument 43-101 and has reviewed and approved the technical disclosures in this press release.

Sampling and Assaying Disclosure

Analytical samples for the Drill Program were taken by sawing HQ diameter core into equal halves on site, with one half sent to ALS Chemex in Val D’or, Quebec, Canada for preparation and analysis. All samples were assayed using a 50 g nominal weight fire with assay atomic absorption finish (Au-AA24) and multi-element four acid digest ICP-AES/ICP-MS method (ME-MS61). Where Au-AA24 results were greater than 10 ppm by Au-AA24 were re-assayed with 50 g nominal weight fire assay with gravimetric finish (Au-GRA22). QA/QC programs using internal standard samples and blanks, field and lab duplicates, and lab standards and blanks indicate good overall accuracy and precision.

About Fury Gold Mines Limited

Fury Gold Mines Limited is a well-financed Canadian-focused exploration company advancing its 100% owned Eau Claire gold project towards development. The Company holds a 5.8% equity position in Contango Silver and Gold Inc. and is led by a management team and board of directors with proven success in financing and advancing exploration assets. Fury intends to grow its gold portfolio through rigorous project evaluation and exploration excellence. Fury is committed to upholding the highest industry standards for corporate governance, environmental stewardship, community engagement and sustainable mining. For more information on Fury Gold Mines, visit www.furygoldmines.com.

For further information on Fury Gold Mines Limited, please contact:

Margaux Villalpando, Investor Relations
Tel: (844) 601-0841
Email: info@furygoldmines.com
Website: www.furygoldmines.com

Forward-Looking Statements and Additional Cautionary Language

This news release includes certain statements that may be deemed to be “forward-looking statements” within the meaning of applicable securities laws, which statements relate to the future exploration operations of the Company and may include other statements that are not historical facts. Specific forward-looking statements contained in this news release includes information relating to the Company’s ongoing exploration program at the Eau Claire project.

Although the Company believes that the assumptions and expectations reflected in those forward-looking statements were reasonable at the time such statements were made, there can be no certainty that such assumptions and expectations will prove to be materially correct. Mineral exploration is a high-risk enterprise.

Readers should refer to the risks discussed in the Company’s Annual Information Form and MD&A for the year ended December 31, 2025 and subsequent continuous disclosure filings with the Canadian Securities Administrators available at www.sedarplus.ca and the Company’s Annual Report available at www.sec.gov. Readers should not place heavy reliance on forward-looking information, which is inherently uncertain.

Photos accompanying this announcement are available at

https://www.globenewswire.com/NewsRoom/AttachmentNg/4940dafd-30d0-465d-a5e9-1407fec8c622

https://www.globenewswire.com/NewsRoom/AttachmentNg/08fc39ab-9577-4fdf-a40a-51a3653a2f09

Proceeds intended to support the proposed acquisition and planned conversion of a computing center in Youngstown, Ohio

NEW YORK, Oct. 26, 2026 (GLOBE NEWSWIRE) — Valor Energy Inc. (Nasdaq: VAI) (“Valor Energy” or the “Company”) today announced that on October 19, 2026, it entered into a securities purchase agreement with certain investors for a private placement of 2,145,923 shares of the Company’s common stock at a purchase price of US$2.33 per share, for aggregate gross proceeds of approximately US$5.0 million, before deducting offering expenses.

The financing follows the Company’s recent announcement that it has entered into an agreement to acquire all of the outstanding equity interests of the company that holds a computing center in Youngstown, Ohio. The Company intends to use the proceeds to support its proposed acquisition and planned conversion of the Youngstown facility as part of its AI data center development plans.

Use of Proceeds

The Company intends to use the net proceeds primarily for the development of its AI data center business, including:

• Youngstown acquisition: funding the US$3.6 million consideration, subject to adjustment under the acquisition agreement, for the proposed acquisition of all outstanding equity interests of the entity holding the computing center located at 1911 Logan Avenue, Youngstown, Ohio, which holds 18MVA of power capacity under an existing 23kV utility interconnection with Ohio Edison. Completion of the acquisition remains subject to due diligence and other closing conditions, and there can be no assurance that it will be completed on the terms described or at all.
• AI data center conversion: following completion of the acquisition, funding design, construction, equipment procurement and permitting work for the planned conversion of the existing approximately 30,890-square-foot facility into an AI data center intended to support AI and high-performance computing (HPC) workloads.
• Business development: building the operational capabilities and customer relationships needed to bring AI computing capacity to market, and evaluating additional sites with existing power infrastructure in the United States.
• Working capital and general corporate purposes.

Valor Energy’s strategy is to pursue acquisitions of sites with existing power infrastructure for potential AI data center development in the United States. The Company intends to use the net proceeds primarily to support the proposed Youngstown acquisition and planned conversion. The timing and scope of development remain subject to completion of the acquisition, further design, construction, equipment and permitting work, and the availability of sufficient funding.

“We intend to use the proceeds from this financing primarily toward the proposed Youngstown acquisition and the initial stages of its planned conversion into an AI data center,” said Dave Nichols, strategic advisor to Valor Energy Inc. “Completion of the acquisition and development site remains subject to closing conditions and further development work such as the availability of sufficient funding. We appreciate our investors’ support as we pursue these plans.”

The securities offered in the private placement have not been registered under the Securities Act of 1933, as amended, or applicable state securities laws, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful. For further details of this transaction, please see the Form 8-K filed with the Securities and Exchange Commission on October 23, 2026.

About Valor Energy Inc.

Valor Energy Inc. (Nasdaq: VAI) is a Nasdaq-listed company that historically operated automobile transaction and related services businesses and is now pursuing opportunities in digital infrastructure, and energy, including U.S. AI and data center infrastructure.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the private placement, the anticipated use of proceeds, the completion of the Youngstown acquisition, and the conversion of the Youngstown facility into an AI data center. These statements are based on current expectations and are subject to risks and uncertainties, including market conditions, satisfaction of closing conditions, the results of due diligence, the availability of power, equipment and permits, construction costs and timelines, uncertainty regarding the usable IT load supported by the site’s power infrastructure, the continuation of existing power arrangements following closing, the availability and cost of additional financing for development, and other risks described in the Company’s filings with the U.S. Securities and Exchange Commission. The Company undertakes no obligation to update these statements except as required by law.

Investor Relations Contact

Valor Energy Inc.
Email: Admin@valorenergy.ai

FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY
A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
Rule 8.3 of the Takeover Code (the “Code”)

1.        KEY INFORMATION

(a)   Full name of discloser:	Man Group PLC
(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):         The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.
(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:         Use a separate form for each offeror/offeree	RHI Magnesita N.V.
(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:
(e)   Date position held/dealing undertaken:         For an opening position disclosure, state the latest practicable date prior to the disclosure	23/10/2026
(f)   In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?	YES Offeree: Vesuvius plc

2.        POSITIONS OF THE PERSON MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a)      Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security:	€1 ordinary
	Interests		Short positions
	Number	%	Number	%
(1)   Relevant securities owned and/or controlled:	1,164,753	2.45
(2)   Cash-settled derivatives:	310,513	0.65
(3)   Stock-settled derivatives (including options) and agreements to purchase/sell:
TOTAL:	1,475,266	3.11

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b)      Rights to subscribe for new securities (including directors’ and other employee options)

Class of relevant security in relation to which subscription right exists:
Details, including nature of the rights concerned and relevant percentages:

3.        DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a)        Purchases and sales

Class of relevant security

Purchase/sale

Number of securities

Price per unit

(b)        Cash-settled derivative transactions

Class of relevant security	Product description e.g. CFD	Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position	Number of reference securities	Price per unit
€1 ordinary	Equity Swap	Reducing a long position	324	25.3153 EUR
€1 ordinary	Equity Swap	Reducing a long position	607	25.3438 EUR
€1 ordinary	Equity Swap	Reducing a long position	868	25.3153 EUR
€1 ordinary	Equity Swap	Reducing a long position	1,794	25.3438 EUR
€1 ordinary	Equity Swap	Reducing a long position	9	25.3153 EUR
€1 ordinary	Equity Swap	Reducing a long position	10	25.3438 EUR
€1 ordinary	Equity Swap	Reducing a long position	2,124	25.3153 EUR
€1 ordinary	Equity Swap	Reducing a long position	3,995	25.3438 EUR

        
(c)        Stock-settled derivative transactions (including options)

(i)        Writing, selling, purchasing or varying

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type e.g. American, European etc.

Expiry date

Option money paid/ received per unit

(ii)        Exercise

Class of relevant security

Product description e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

(d)        Other dealings (including subscribing for new securities)

Class of relevant security

Nature of dealing e.g. subscription, conversion

Details

Price per unit (if applicable)

4.        OTHER INFORMATION

(a)        Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

None

(b)        Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i)   the voting rights of any relevant securities under any option; or (ii)   the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

None

(c)        Attachments

Is a Supplemental Form 8 (Open Positions) attached?

NO

Date of disclosure:	26/10/2026
Contact name:	Molly Childs
Telephone number:	+44 20 7144 3714

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY
A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
Rule 8.3 of the Takeover Code (the “Code”)

1.        KEY INFORMATION

(a)   Full name of discloser:	Man Group PLC
(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):         The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.
(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:         Use a separate form for each offeror/offeree	Sthree plc
(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:
(e)   Date position held/dealing undertaken:         For an opening position disclosure, state the latest practicable date prior to the disclosure	23/10/2026
(f)   In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?	NO

2.        POSITIONS OF THE PERSON MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a)      Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security:	1p ordinary
	Interests		Short positions
	Number	%	Number	%
(1)   Relevant securities owned and/or controlled:	6,820,075	5.61
(2)   Cash-settled derivatives:	3,777,607	3.10	15,497	0.01
(3)   Stock-settled derivatives (including options) and agreements to purchase/sell:
TOTAL:	10,597,682	8.72	15,497	0.01

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b)      Rights to subscribe for new securities (including directors’ and other employee options)

Class of relevant security in relation to which subscription right exists:
Details, including nature of the rights concerned and relevant percentages:

3.        DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a)        Purchases and sales

Class of relevant security

Purchase/sale

Number of securities

Price per unit

(b)        Cash-settled derivative transactions

Class of relevant security	Product description e.g. CFD	Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position	Number of reference securities	Price per unit
1p ordinary	Equity swap	Reducing a long position	7,384	2.9422 GBP
1p ordinary	Equity swap	Reducing a long position	21,103	2.9422 GBP
1p ordinary	Equity swap	Reducing a long position	144	2.9422 GBP
1p ordinary	Equity swap	Reducing a long position	48,462	2.9422 GBP

        
(c)        Stock-settled derivative transactions (including options)

(i)        Writing, selling, purchasing or varying

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type e.g. American, European etc.

Expiry date

Option money paid/ received per unit

(ii)        Exercise

Class of relevant security

Product description e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

(d)        Other dealings (including subscribing for new securities)

Class of relevant security

Nature of dealing e.g. subscription, conversion

Details

Price per unit (if applicable)

4.        OTHER INFORMATION

(a)        Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

None

(b)        Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i)   the voting rights of any relevant securities under any option; or (ii)   the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

None

(c)        Attachments

Is a Supplemental Form 8 (Open Positions) attached?

NO

Date of disclosure:	26/10/2026
Contact name:	Molly Childs
Telephone number:	+44 20 7144 3714

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY
A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
Rule 8.3 of the Takeover Code (the “Code”)

1.        KEY INFORMATION

(a)   Full name of discloser:	Man Group PLC
(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):         The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.
(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:         Use a separate form for each offeror/offeree	Vesuvius plc
(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:
(e)   Date position held/dealing undertaken:         For an opening position disclosure, state the latest practicable date prior to the disclosure	23/10/2026
(f)   In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?	YES Offeror: RHI Magnestia N.V.

2.        POSITIONS OF THE PERSON MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a)      Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security:	10p ordinary
	Interests		Short positions
	Number	%	Number	%
(1)   Relevant securities owned and/or controlled:	13,201,997	5.31
(2)   Cash-settled derivatives:	906,843	0.36	499,224	0.20
(3)   Stock-settled derivatives (including options) and agreements to purchase/sell:
TOTAL:	14,108,840	5.68	499,224	0.20

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b)      Rights to subscribe for new securities (including directors’ and other employee options)

Class of relevant security in relation to which subscription right exists:
Details, including nature of the rights concerned and relevant percentages:

3.        DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a)        Purchases and sales

Class of relevant security	Purchase/sale	Number of securities	Price per unit
10p ordinary	Sale	58,333	4.4363 GBP

(b)        Cash-settled derivative transactions

Class of relevant security	Product description e.g. CFD	Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position	Number of reference securities	Price per unit
10p ordinary	Equity Swap	Reducing a long position	1,829	4.4340 GBP
10p ordinary	Equity Swap	Reducing a long position	4,061	4.4363 GBP
10p ordinary	Equity Swap	Reducing a long position	5,168	4.4340 GBP
10p ordinary	Equity Swap	Reducing a long position	10,821	4.4363 GBP
10p ordinary	Equity Swap	Reducing a long position	32	4.4340 GBP
10p ordinary	Equity Swap	Reducing a long position	160	4.4363 GBP
10p ordinary	Equity Swap	Reducing a long position	12,094	4.4340 GBP
10p ordinary	Equity Swap	Reducing a long position	26,625	4.4363 GBP

        
(c)        Stock-settled derivative transactions (including options)

(i)        Writing, selling, purchasing or varying

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type e.g. American, European etc.

Expiry date

Option money paid/ received per unit

(ii)        Exercise

Class of relevant security

Product description e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

(d)        Other dealings (including subscribing for new securities)

Class of relevant security

Nature of dealing e.g. subscription, conversion

Details

Price per unit (if applicable)

4.        OTHER INFORMATION

(a)        Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

None

(b)        Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i)   the voting rights of any relevant securities under any option; or (ii)   the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

None

(c)        Attachments

Is a Supplemental Form 8 (Open Positions) attached?

NO

Date of disclosure:	26/10/2026
Contact name:	Molly Childs
Telephone number:	+44 20 7144 3714

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

BEIJING, Oct. 26, 2026 (GLOBE NEWSWIRE) — InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced its third quarter 2026 results and business highlights for the nine-months ended September 30, 2026.

In the first three quarters of 2026, driven by strong commercial execution and global business development collaborations, the Company’s revenue grew 88.2% year-on-year (YoY) to RMB 2.1 billion, and net profit reached RMB 648.3 million, as the Company sustained profitability.

The Company also continued to accelerate its globalization, entering into a strategic collaboration with Eli Lilly that reflects global recognition of its innovation capabilities. The company has been continuously accelerating its pipeline development, with 14 registrational clinical trials ongoing and five new molecules entering the clinic this year. InnoCare further advanced its strategy of innovation, commercialization and globalization, building stronger momentum for long-term growth.

Financial Highlights

Revenue grew by 88.2% YoY to RMB 2.1 billion in the first three quarters of 2026, driven mainly by robust commercial growth and global business development collaborations.

Drug sales increased by 41.5% YoY to RMB 1.4 billion for the 9 months ended September 30, 2026, driven by robust growth of orelabrutinib and contributions from the newly launched tafasitamab and zurletrectinib.

Profit reached RMB 648.3 million, compared with a loss of RMB 72.0 million in the same period, mainly due to continued commercial growth and global BD collaborations.

Research and Development Investment increased by 16.1% YoY to RMB 785.1 million for the 9 months ended September 30, 2026, reflecting the advancement of additional Phase III clinical trials, as well as increased investment in new technology platforms.

Accelerating Globalization

In the third quarter of 2026, InnoCare continued to accelerate its globalization by entering into a strategic research collaboration and license agreement with Eli Lilly. Leveraging its drug discovery platform and extensive research experience, the Company will discover and advance up to five innovative target programs, with a total deal value of up to US$ 3.35 billion. The collaboration underscores global recognition of the Company’s R&D capabilities and the international competitiveness of its drug discovery platform.

Dr. Jasmine Cui, the Co-founder, Chairwoman, and CEO of InnoCare, said, “In the first three quarters of 2026, we sustained profitability, maintained robust commercial growth, and accelerated globalization. Our collaboration with Zenas continued to advance with increasing value realization, and we entered into a strategic collaboration with Eli Lilly, fully demonstrating our capabilities in global collaboration. Meanwhile, projects across our oncology and autoimmune pipelines progressed rapidly in China and globally, in line with our commitment to benefit patients worldwide.”

Robust Commercial Growth

Leveraging a diversified and highly competitive product portfolio and strong commercial execution, the Company’s drug sales maintained rapid growth in the first three quarters of 2026, increasing by 41.5% YoY to RMB 1.4 billion.

In 2026, all four approved indications of orelabrutinib were included in the updated National Reimbursement Drug List (NRDL). Orelabrutinib sales grew rapidly following the NRDL inclusion of the first line chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) indication, while orelabrutinib maintained its exclusive indication advantage in marginal zone lymphoma (MZL). Additionally, both tafasitamab and zurletrectinib have been approved for marketing and have begun to contribute to sales. Tafasitamab is the first CD19 antibody approved for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in China, and the next-generation TRK inhibitor, zurletrectinib, has been prescribed in hospitals across China.

Accelerating Innovation

Enhancing Competitive Advantage in Hemato-Oncology

As the first BCL2 inhibitor granted Breakthrough Therapy Designation (BTD) in China, mesutoclax (ICP-248) is advancing five registrational clinical trials. The latest data from the program will be presented at the 68th American Society of Hematology (ASH) Annual Meeting in New Orleans from December 12-15, 2026.

1) The registrational Phase III trial of mesutoclax with orelabrutinib in 1L CLL/SLL has completed patient enrollment.
2) The registrational Phase II clinical trial of mesutoclax in BTK inhibitor-treated mantle cell lymphoma (MCL) has completed patient enrollment and received BTD. It is the first BCL2 inhibitor to receive BTD recognition in China.
3) The registrational Phase III clinical trial of mesutoclax in combination with orelabrutinib in r/r MCL is ongoing in China.
4) The head-to-head registrational Phase III trial of mesutoclax with azacitidine versus venetoclax with azacitidine in treatment naïve (TN) acute myeloid leukemia (AML) was initiated in China.
5) The Phase III clinical trial of mesutoclax in combination with orelabrutinib for the treatment of patients with marginal zone lymphoma (MZL) who have received at least one prior therapy has been initiated, and the combination has been granted BTD in China.

In addition, global clinical development of mesutoclax in AML and myelodysplastic syndrome (MDS) is accelerating in China, the U.S., and Australia. The latest data will be presented at the 68th American Society of Hematology (ASH) Annual Meeting in 2026.

Accelerating Autoimmune Pipeline, Building Second Growth Curve

Orelabrutinib

The NDA submission for orelabrutinib in Immune thrombocytopenia（ITP）has been accepted in China, marking orelabrutinib’s first NDA acceptance in an autoimmune indication and a significant milestone in its expansion beyond hematologic malignancies into autoimmune diseases. The Phase III clinical data will be presented at the 68th ASH Annual Meeting in 2026.

The registrational Phase III clinical trial of orelabrutinib in systemic lupus erythematosus (SLE) has been accelerating patient enrollment. Orelabrutinib is the first BTK inhibitor to demonstrate significant efficacy in a Phase IIb clinical trial in SLE.

Two global registrational Phase III clinical trials of orelabrutinib in primary progressive multiple sclerosis (PPMS) and secondary progressive multiple sclerosis (SPMS) are ongoing in collaboration with Zenas. Multiple studies were presented at the 10th Joint ACTRIMS-ECTRIMS Meeting in 2026, fully demonstrating the significant clinical potential of orelabrutinib in SPMS and PPMS.

Two Differentiated Oral TYK2 Inhibitors

Soficitinib (ICP-332) and fadeucravacitinib (ICP-488) have delivered multiple pivotal Phase II/III clinical readouts that met primary endpoints.

Soficitinib

1) The Phase III clinical trial of soficitinib in patients with moderate to severe atopic dermatitis (AD) met primary endpoints.
2) The Phase II portion of the Phase II/III trial in non-segmental vitiligo has met its primary endpoint. The Company will accelerate Phase III clinical trials.
3) The global Phase II clinical trial for prurigo nodularis (PN) has continued patient enrollment in China, U.S. and Europe.
4) The Phase II/III clinical trial for moderate‑to‑severe chronic spontaneous urticaria (CSU) has completed patient enrollment.
5) The Phase II clinical trial for moderate‑to‑severe plaque psoriasis has completed patient enrollment.
6) The Phase II clinical trial in adolescent patients with moderate-to-severe AD has completed patient enrollment.

Fadeucravacitinib

1) The Phase III clinical trial in patients with moderate-to-severe plaque psoriasis achieved primary endpoints.
2) The Phase II clinical trial in cutaneous lupus erythematosus (CLE) is being expedited.
3) The Phase II clinical trial in patients with Sjögren’s syndrome (SS) is ongoing.

Other Autoimmune Pipelines

ICP-054, a novel oral IL-17AA/AF inhibitor, has successfully enrolled healthy volunteers. The single-ascending-dose (SAD) and multiple-ascending-dose (MAD) portions are being conducted in collaboration with Zenas, with Phase I study completion expected by the end of 2026.

ICP-538, the first VAV1 degrader approved to enter clinical trials in China and the second globally, has successfully enrolled patients, with the Phase I clinical study expected to complete by the end of the year. ICP-538 is a novel, potent, highly selective, orally administered molecular glue degrader targeting VAV1, a key signaling protein downstream of the T-cell and B-cell receptors. ICP-538 is being developed for the treatment of hard-to-treat autoimmune diseases, such as inflammatory bowel disease (IBD), SLE, and MS.

ICP-B161, a novel bispecific antibody targeting TL1A and IL-23p19, has been approved for clinical trials for the treatment of autoimmune diseases, including IBD. In preclinical studies, ICP-B161 demonstrated good efficacy, including significant inhibition of colitis-related symptoms.

Accelerating Solid Tumor Pipeline Development

Zurletrectinib, the next-generation TRK inhibitor, was granted priority review for the treatment of pediatric patients (ages 2–12) with solid tumors harboring NTRK fusions, and the NDA application has been accepted.

The Company’s highly differentiated ADC technology platform leverages unique linker-potent payload (LP) technology. Built on this platform, the Company will continue to develop multiple ADC drug candidates with highly differentiated efficacy and safety profiles, bringing a new generation of treatment options to patients with cancer. To date, three innovative ADC candidates have entered clinical development, including the Company’s first bispecific ADC.

1) ICP-B794, a novel B7-H3 targeted ADC, has accelerated Phase I dose-escalation trial, offering a promising treatment for solid tumors such as lung cancer, esophageal cancer, nasopharyngeal cancer, head and neck squamous cell carcinomas, prostate cancer, and others.
2) ICP-B208, a novel CDH17-targeted ADC, has entered clinical development, with patient enrollment underway. ICP-B208 is being developed for the treatment of gastrointestinal cancers, including gastric, colorectal, pancreatic ductal adenocarcinoma, and cholangiocarcinoma.
3) ICP-B381, a novel bi-specific ADC targeting PSMA and STEAP1, has entered clinical development in China for the treatment of solid tumors, including prostate cancer. In preclinical studies, ICP-B381 demonstrated robust and dose-dependent antitumor activities.

InnoCare will accelerate the coordinated advancement of innovation, commercialization and globalization, continuing to unlock the value of its innovation globally for the benefit of patients worldwide.

To know more about the detailed financial data and business updates of InnoCare 2026 Q3 results, please log in to https://www.innocarepharma.com/en/investor/home

Conference Call Information

InnoCare will host a conference call at 9:00 a.m. Beijing time in Chinese on Oct. 27, 2026. Participants must register in advance of the conference call through the below link: https://s.comein.cn/y7dbuh3u.

InnoCare Forward-looking Statements

This report contains the disclosure of some forward-looking statements. Except for statements of facts, all other statements can be regarded as forward-looking statements, that is, about our or our management’s intentions, plans, beliefs, or expectations that will or may occur in the future. Such statements are assumptions and estimates made by our management based on its experience and knowledge of historical trends, current conditions, expected future development and other related factors. This forward-looking statement does not guarantee future performance, and actual results, development and business decisions may not match the expectations of the forward-looking statement. Our forward-looking statements are also subject to a large number of risks and uncertainties, which may affect our short-term and long-term performance.

About InnoCare Pharma

InnoCare (HKEX: 09969; SSE: 688428) is a commercial stage biopharmaceutical company committed to discovering, developing, and commercializing innovative drugs for the treatment of cancers and autoimmune diseases, two therapeutic areas with unmet medical needs worldwide. InnoCare has established comprehensive innovation platforms for drug discovery. To date, the Company has developed a robust product pipeline comprising three approved drugs (orelabrutinib, tafasitamab and zurletrectinib), more than ten innovative drug candidates in clinical development, and multiple programs in preclinical stages. InnoCare has branches in Beijing, Nanjing, Shanghai, Guangzhou, Hong Kong, and the United States. For more information about InnoCare, please visit https://www.innocarepharma.com/en and follow us on LinkedIn.

Contact
Media Chunhua Lu 86-10-66609879                         chunhua.lu@innocarepharma.com	Investors 86-10-66609999 ir@innocarepharma.com

Earnings Release: Wednesday, October 28, 2026, Before Market Opens

MONACO, Oct. 26, 2026 (GLOBE NEWSWIRE) — Costamare Inc. (NYSE:CMRE) (the “Company”) announced today that it will release its results for the third quarter ended September 30, 2026 before the market opens in New York on October 28, 2026.

Results Presentation:
A presentation of the Company’s financial results for the third quarter of 2026 will be posted on the Costamare Inc. website (www.costamare.com).

About Costamare Inc.
Costamare Inc. is one of the world’s leading owners and providers of containerships for charter. The Company has 52 years of history in the international shipping industry and a fleet of 69 containerships in the water (including two vessels we have agreed to sell), with a total capacity of approximately 520,000 TEU. The Company also has 22 newbuild containerships under construction and has agreed to acquire two secondhand containerships, which together represent a total capacity of approximately 152,600 TEU. The Company also participates in a leasing business. The Company’s common stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock trade on the New York Stock Exchange under the symbols “CMRE”, “CMRE PR B”, “CMRE PR C” and “CMRE PR D”, respectively.

Forward-Looking Statements
This press release contains “forward-looking statements”. In some cases, you can identify these statements by forward-looking words such as “believe”, “intend”, “anticipate”, “estimate”, “project”, “forecast”, “plan”, “potential”, “may”, “should”, “could”, “expect” and similar expressions. These statements are not historical facts but instead represent only the Company’s belief regarding future results, many of which, by their nature, are inherently uncertain and outside of the Company’s control. It is possible that actual results may differ, possibly materially, from those anticipated in these forward-looking statements. For a discussion of some of the risks and important factors that could affect future results, see the discussion in the Company’s Annual Report on Form 20-F (File No. 001-34934) under the caption “Risk Factors”.

Company Contacts:
Gregory Zikos – Chief Financial Officer
Konstantinos Tsakalidis – Business Development, Investor Relations

Costamare Inc., Monaco
Tel: (+377) 93 25 09 40
Email: ir@costamare.com